JACKSONVILLE, Fla. — Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC in laboratory animals led to a significant decrease in pancreatic tumor growth and spread.
The discovery, reported in the March 1 issue of Cancer Research, is especially encouraging, they say, because an experimental agent that targets PKC is already being tested in patients at Mayo Clinic.